Literature DB >> 10944563

Racecadotril in the treatment of acute watery diarrhea in children.

E Salazar-Lindo1, J Santisteban-Ponce, E Chea-Woo, M Gutierrez.   

Abstract

BACKGROUND: Racecadotril (acetorphan), an enkephalinase inhibitor with antisecretory and antidiarrheal actions, is an effective and safe treatment for acute diarrhea in adults and children. Whether treatment with racecadotril and oral rehydration therapy is more effective than treatment with oral rehydration alone in hospitalized children with acute watery diarrhea is not known.
METHODS: We treated 135 boys 3 to 35 months of age who had watery diarrhea of five days' duration or less with racecadotril (1.5 mg per kilogram of body weight orally every eight hours) or placebo, in addition to oral rehydration solution. The primary end point was the 48-hour stool output (measured in grams); the total stool output, duration of diarrhea, and total intake of oral rehydration solution were also measured.
RESULTS: The mean (+/-SE) 48-hour stool output was 92+/-12 g per kilogram in the racecadotril group and 170+/-15 g per kilogram in the placebo group (P<0.001), a 46 percent reduction with racecadotril. The results were similar among the 73 boys with rotavirus infections. The total stool output was 157+/-27 g per kilogram in the racecadotril group and 331+/-39 g per kilogram in the placebo group (P<0.001). The median duration of diarrhea was significantly less (P<0.001) in the racecadotril group (28 hours regardless of rotavirus status) than in the placebo group (72 and 52 hours, respectively, for rotavirus-positive and rotavirus-negative patients). The intake of oral rehydration solution was significantly lower in the racecadotril group than in the placebo group (P<0.001). Racecadotril was well tolerated; only seven patients taking racecadotril had adverse effects, which were all mild and transient.
CONCLUSIONS: In young boys with acute watery diarrhea, racecadotril is an effective and safe treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944563     DOI: 10.1056/NEJM200008173430703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  52 in total

Review 1.  Novel targets for the control of secretory diarrhoea.

Authors:  M J G Farthing
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 3.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

4.  Hypersensitivity to racecadotril: a case report.

Authors:  Eleonora Nucera; Domenico Schiavino; Giorgia Altomonte; Alessandro Buonomo; Vito Sabato; Giampiero Patriarca
Journal:  Eur J Pediatr       Date:  2006-01-28       Impact factor: 3.183

Review 5.  [Treating travelers' diarrhea. When should medication be given?].

Authors:  G Birkenfeld
Journal:  Internist (Berl)       Date:  2007-12       Impact factor: 0.743

6.  Treatment of diarrheal disease.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-09       Impact factor: 2.253

Review 7.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

8.  Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial.

Authors:  N H Alam; H Ashraf; W A Khan; M M Karim; G J Fuchs
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  I, 3. The enteric nervous system and infectious diarrhea.

Authors:  Ove Lundgren; Lennart Svensson
Journal:  Perspect Med Virol       Date:  2004-09-14

10.  Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes.

Authors:  Luca Gallelli; Manuela Colosimo; Grazia A Tolotta; Daniella Falcone; Laura Luberto; Lucia S Curto; Pierandrea Rende; Francesca Mazzei; Norma M Marigliano; Giovambattista De Sarro; Salvatore Cucchiara
Journal:  Eur J Clin Pharmacol       Date:  2009-11-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.